- TransCode Therapeutics (RNAZ, Financial) adjourns its Special Meeting due to insufficient quorum.
- The Adjourned Special Meeting is rescheduled for May 2, 2025, at 9:30 a.m. ET.
- Key proposals include a reverse stock split and potential further adjournment needs.
TransCode Therapeutics, Inc. (RNAZ) announced the adjournment of its Special Meeting initially planned for April 21, 2025, as it did not achieve the necessary quorum, with only 12.73% of eligible shares represented. The meeting has been rescheduled to convene as a virtual Adjourned Special Meeting on May 2, 2025, at 9:30 a.m. Eastern Time.
The meeting's agenda includes two crucial proposals. Proposal One seeks approval for a reverse stock split, which could range from a 1:10 to 1:40 ratio, intended to adjust the company's share structure. Proposal Two allows for the potential adjournment of the meeting if there is an insufficient vote count on the reverse stock split proposal.
Stockholders of record as of April 2, 2025, are entitled to vote on the proposals. Voting can be conducted through various methods: mail, internet, telephone, or directly during the virtual meeting at www.virtualshareholdermeeting.com/RNAZ2025SM2. To ensure their votes are counted, shareholders are encouraged to submit their votes by 11:59 p.m. Eastern Time on May 1, 2025, or participate in the live webcast.
